<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01923857</url>
  </required_header>
  <id_info>
    <org_study_id>ZA-104</org_study_id>
    <nct_id>NCT01923857</nct_id>
  </id_info>
  <brief_title>Evaluation of Pharmacokinetic and Safety Profile of Androxal in Male Subjects With Impaired Renal Function</brief_title>
  <official_title>A Single-Dose, Open-Label Study to Evaluate the Pharmacokinetics and Safety Profile of Androxal in Male Subjects With Impaired Renal Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repros Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repros Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  To determine and compare the pharmacokinetics (PK) of a single dose of 25 mg Androxal in&#xD;
           overweight male subjects with various stages of renal impairment and in volunteers with&#xD;
           normal renal function.&#xD;
&#xD;
        -  To compare the safety profile of a single dose of 25 mg Androxal in overweight male&#xD;
           subjects with various stages of renal impairment and in volunteers with normal renal&#xD;
           function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>24 hours</time_frame>
    <description>Pharmacokinetic parameters calculated as a ratio in subjects with mild or moderate renal impairment to normal after a single dose of 25 mg Androxal.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Secondary Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy males age 18-80 with a body mass index(BMI) 25-42 mg/m^2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Males with mild renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m^2 (creatinine clearance 50-80 mL/min).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate Renal Impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Males with moderate renal impairment age 18-80 with a body mass index(BMI) 25-42 mg/m^2 (creatinine clearance 30-50 mL/min).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe renal impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Androxal 25 mg</intervention_name>
    <arm_group_label>Healthy Volunteers</arm_group_label>
    <arm_group_label>Mild Renal Impairment</arm_group_label>
    <arm_group_label>Moderate Renal Impairment</arm_group_label>
    <arm_group_label>Severe renal impairment</arm_group_label>
    <other_name>enclomiphene citrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects with Impaired Renal Function:&#xD;
&#xD;
        Subjects with various stages of impaired renal function must meet all of the following&#xD;
        inclusion criteria at screening will be considered for admission to the study:&#xD;
&#xD;
          1. Speak, read, and understand English or Spanish and is willing and able to provide&#xD;
             written informed consent on an Institutional Review Board (IRB)-approved form prior to&#xD;
             the initiation of any study procedures;&#xD;
&#xD;
          2. Male, between the ages of 18 and 80 years with Body Mass Index (BMI) between 25 and&#xD;
             42, inclusive, are preferred.&#xD;
&#xD;
          3. Subjects must meet the criteria of mildly (creatinine clearance 50-80 mL/min) or&#xD;
             moderately (creatinine clearance 30-50 mL/min) impaired renal function. The&#xD;
             Investigator will assess the renal impairment category of each subject. Substantiation&#xD;
             for the diagnosis must be indicated in source documents; (See Appendix B)&#xD;
&#xD;
          4. Subjects must have evidence of stable renal impairment as determined by the&#xD;
             Investigator (See Section 9.3.2, Day -1)&#xD;
&#xD;
          5. If on medications for treatment of the complications of renal disease, and other&#xD;
             concomitant chronic illnesses, subjects must have been taking the medications at a&#xD;
             stable dose for at least 10 days prior to the first Androxal dosing date and are then&#xD;
             to be continued at the same dose for the duration of the study. The medications must&#xD;
             be recorded in source documents;&#xD;
&#xD;
          6. Subject is willing to remain in the clinic for the screening visit (approximately 1&#xD;
             day for the screening visit) and for the treatment visit (approximately 3 days);&#xD;
&#xD;
          7. Non-smokers are preferred, but as this is a very restricted population light to&#xD;
             moderate smoking will be allowed (no more than 10 cigarettes/day);&#xD;
&#xD;
          8. Must be able to swallow gelatin capsules;&#xD;
&#xD;
        Subjects with Normal Renal Function:&#xD;
&#xD;
        Healthy volunteers meeting all of the following inclusion criteria at screening will be&#xD;
        considered for admission to the study:&#xD;
&#xD;
          1. Speak, read, and understand English or Spanish and is willing and able to provide&#xD;
             written informed consent on an IRB-approved form prior to the initiation of any study&#xD;
             procedures;&#xD;
&#xD;
          2. Male, between the ages of 18 and 60 years with Body Mass Index (BMI) between 25 and&#xD;
             39, inclusive;&#xD;
&#xD;
          3. Creatinine clearance &gt; 80 mL/min;&#xD;
&#xD;
          4. Subjects in the control group, generally matched for age and BMI to patients enrolled&#xD;
             in the test groups: should be ± 20 years of the mean of mildly and moderately renally&#xD;
             impaired subjects included in the study and ± 20% of the average BMI of mildly and&#xD;
             moderately renally impaired subjects;&#xD;
&#xD;
          5. No significant abnormal findings at the screening physical examination as evaluated by&#xD;
             the Investigator;&#xD;
&#xD;
          6. Normal laboratory values or clinically insignificant findings at screening as&#xD;
             determined by the Investigator;&#xD;
&#xD;
          7. Subject is willing to remain in the clinic for the screening visit (approximately 1&#xD;
             day for the first screening visit) and for the treatment visit (approximately 3 days);&#xD;
&#xD;
          8. No tobacco (nicotine products) use for at least three (3) months prior to the study;&#xD;
&#xD;
          9. Must be able to swallow gelatin capsules&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects with Impaired Renal Function&#xD;
&#xD;
        Subjects with various stages of impaired renal function meeting any of the following&#xD;
        exclusion criteria at screening will not be enrolled in the study:&#xD;
&#xD;
          1. Known hypersensitivity to Clomid;&#xD;
&#xD;
          2. Subjects with clinically significant abnormal liver function as determined by the&#xD;
             Investigator;&#xD;
&#xD;
          3. Subjects who are treated with dialysis;&#xD;
&#xD;
          4. A physical illness within three (3) months of the study that would interfere with the&#xD;
             study as determined by the Investigator;&#xD;
&#xD;
          5. Participation in a clinical trial with investigational medication within four (4)&#xD;
             weeks prior to study medication administration;&#xD;
&#xD;
          6. A hematocrit &gt;54% or a hemoglobin &gt;17 g/dL. (Sponsor may approve enrollment of&#xD;
             subjects with hemoglobin up to 17.5 g/dL if the subject is at a location with high&#xD;
             elevation).&#xD;
&#xD;
          7. An acute illness within five (5) days of study medication administration;&#xD;
&#xD;
          8. Uncontrolled hypertension based on the Investigator's assessment at baseline. Subjects&#xD;
             treated for Type II diabetes will be allowed into the study. Newly diagnosed diabetics&#xD;
             need to be treated for at least 48 hours before being enrolled into the study.&#xD;
&#xD;
          9. Positive urine drug or infectious disease screen at the screening visit based on&#xD;
             laboratory testing;&#xD;
&#xD;
         10. A mental condition rendering the subject unable to understand the nature, scope, and&#xD;
             possible consequences of the study and/or evidence of an uncooperative attitude, as&#xD;
             determined by the Investigator;&#xD;
&#xD;
         11. History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary&#xD;
             embolism);&#xD;
&#xD;
         12. History of myocardial infarction, unstable angina, symptomatic heart failure,&#xD;
             ventricular dysrhythmia, or known history of corrected QT interval (QTc) interval&#xD;
             prolongation;&#xD;
&#xD;
         13. The use of prohibited concomitant medications:&#xD;
&#xD;
               -  Drugs that may interfere with cytochrome P450 2D6 (CYP2D6) activity must cease&#xD;
                  for 7 days prior to first dose of study drug;&#xD;
&#xD;
         14. An employee or family member of an employee of the study site or the Sponsor.&#xD;
&#xD;
        Subjects with Normal Renal Function:&#xD;
&#xD;
        Healthy volunteers meeting any of the following exclusion criteria at screening will not be&#xD;
        enrolled in the study:&#xD;
&#xD;
          1. Known hypersensitivity to Clomid;&#xD;
&#xD;
          2. Abnormal screening visit vital signs or clinical laboratory evaluation considered&#xD;
             clinically significant by the Investigator;&#xD;
&#xD;
          3. Subjects with clinically significant abnormal liver function as determined by the&#xD;
             Investigator;&#xD;
&#xD;
          4. Subject with a significant organ abnormality or disease as determined by the&#xD;
             Investigator;&#xD;
&#xD;
          5. A physical illness within three (3) months of the study that would interfere with the&#xD;
             study as determined by the Investigator;&#xD;
&#xD;
          6. Uncontrolled hypertension based on the Investigator's assessment at baseline. Subjects&#xD;
             treated for Type II diabetes will be allowed into the study. Newly diagnosed diabetics&#xD;
             need to be treated for at least 48 hours before being enrolled into the study.&#xD;
&#xD;
          7. A hematocrit &gt;54% or a hemoglobin &gt;17 g/dL. (Sponsor may approve enrollment of&#xD;
             subjects with hemoglobin up to 17.5 g/dL if the subject is at a location with high&#xD;
             elevation).&#xD;
&#xD;
          8. Participation in a clinical trial with investigational medication within four (4)&#xD;
             weeks prior to study medication administration;&#xD;
&#xD;
          9. An acute illness within five (5) days of study medication administration;&#xD;
&#xD;
         10. A mental condition rendering the subject unable to understand the nature, scope, and&#xD;
             possible consequences of the study and/or evidence of an uncooperative attitude, as&#xD;
             determined by the Investigator;&#xD;
&#xD;
         11. History of venous thromboembolic disease (e.g. deep vein thrombosis or pulmonary&#xD;
             embolism);&#xD;
&#xD;
         12. History of myocardial infarction, unstable angina, symptomatic heart failure,&#xD;
             ventricular dysrhythmia, or known history of QTc interval prolongation;&#xD;
&#xD;
         13. The use of prohibited concomitant medications:&#xD;
&#xD;
               -  Drugs that may interfere with CYP2D6 activity must cease for 7 days prior to&#xD;
                  first dose of study drug;&#xD;
&#xD;
         14. An employee or family member of an employee of the study site or the Sponsor.&#xD;
&#xD;
         15. Positive urine drug or infectious disease screen at the screening visit based on&#xD;
             laboratory testing;&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.reprosrx.com</url>
    <description>Sponsor Web Site</description>
  </link>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>August 13, 2013</study_first_submitted>
  <study_first_submitted_qc>August 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 16, 2013</study_first_posted>
  <last_update_submitted>August 7, 2014</last_update_submitted>
  <last_update_submitted_qc>August 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 11, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Insufficiency</mesh_term>
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

